Investigators confirmed an association between fatty liver disease related to metabolic dysfunction (MAFLD) and chronic kidney disease (CKD), and stressed a greater focus on treating MAFLD is needed to help manage risks.
In a recent study, metabolic dysfunction-associated fatty liver disease (MAFLD) was found to be associated with risk of chronic kidney disease (CKD), suggesting a greater focus on treating MAFLD as a preventative measure is needed.
The retrospective cross-sectional study, published in the Journal of Diabetes Investigation, clarified that although patients with MAFLD were at an increased risk of CKD compared with patients without FLD, patients with FLD without metabolic dysfunction (MD) were not at risk of CKD.
In the past, nonalcoholic FLD (NAFLD) was used to convey the high risk of hepatic disease progression because of its close relationship with CKD. But because the definition of NAFLD requires the exclusion of heavy drinking and other chronic liver diseases, MAFLD is hypothesized to be a more practical and precise definition for high risk. However, results from previous cross-sectional studies assessing the connection between MAFLD and CKD have been inconsistent.
The NAFLD in Gifu Area, Longitudinal Analysis (NAGALA) study comprised of patients enrolled in a medical health checkup program at Asahi University Hospital in Japan between January 2004 and December 2014. Data were collected from the participants' medical history and lifestyle factors were reported via self-completed questionnaires. MAFLD was defined by the presence of fatty liver disease along with either being overweight or obese, having type 2 diabetes, or having metabolic dysregulation without being overweight.
Among the 27,941 individuals originally identified, 27,371 were included in the cross-sectional study and 16,938 were included in the retrospective cohort study. The average (SD) age of the cohort was 45.7 (10.1) years and 59.0% were men.
In the cross-sectional study, 14.1% of the patients had CKD, 49.0% had MD, and 23.1% had FLD. Additionally, 48.7% patients did not have FLD or MD, 28.2% had MD but not FLD, 2.3% had non-MD FLD, and 20.8% had MAFLD. The group with MAFLD was at a risk of CKD (adjusted OR [aOR], 1.83; 95% CI, 1.66-2.01, P < .001) compared with the non-FLD group. However, the group with FLD without MD was not associated with risk of CKD (aOR, 1.02; 95% CI, 0.79-1.33, P = .868).
For the retrospective cohort analysis, 46.3% had MD and 22.0% had FLD, with 19.3% of the cohort having MAFLD. During the median 4.6-year follow-up, 16.5% of patients developed CKD. The incidence rate of CKD cases per 1000 person-years was 21.0 for the group that did not have FLD or MD, 26.1 for the group with FLD but not MD, and 31.1 for the MAFLD group.
Similarly to the cross-sectional analysis, the patients with MAFLD were at risk of incident CKD compared with the patients that had neither FLD or MD (adjusted HR [aHR], 1.30; 95% CI, 1.14-1.36; P < .001). However, the patients with FLD but not MD were not at risk of developing CKD (aHR, 1.11; 95% CI, 0.85-1.41; P = .433).
Investigators suggested the link between MAFLD and CKD may be insulin resistance, which is known to contribute to CKD progression. Metabolic dysfunction is also associated with insulin resistance.
The study had several limitations, including the lack of liver biopsy for FLD diagnosis, limited generalizability, lack of a definition for proteinuria, and the lack of data on insulin, high sensitivity C-reactive protein, and standard oral glucose tolerance tests.
Reference
Hashimoto Y, Hamaguchi M, Okamura T, et al. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig. 2022;13:308-316. doi:10.1111/jdi.13678
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen